BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6515666)

  • 1. Photon activation therapy.
    Fairchild RG; Bond VP
    Strahlentherapie; 1984 Dec; 160(12):758-63. PubMed ID: 6515666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photon activation of iododeoxyuridine: biological efficacy of Auger electrons.
    Laster BH; Thomlinson WC; Fairchild RG
    Radiat Res; 1993 Feb; 133(2):219-24. PubMed ID: 8438063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation enhancement with iodinated deoxyuridine.
    Fairchild RG; Brill AB; Ettinger KV
    Invest Radiol; 1982; 17(4):407-16. PubMed ID: 6813285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iododeoxyuridine radiosensitization by low- and high-energy photons for brachytherapy dose rates.
    Nath R; Bongiorni P; Rockwell S
    Radiat Res; 1990 Dec; 124(3):249-58. PubMed ID: 2263725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of incorporated iododeoxyuridine cellular radiosensitization by photon activation therapy.
    Miller RW; DeGraff W; Kinsella TJ; Mitchell JB
    Int J Radiat Oncol Biol Phys; 1987 Aug; 13(8):1193-7. PubMed ID: 3610707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of IUdR on Rat 9L glioma cell survival for 25-35 keV photon-activated auger electron therapy.
    Alvarez D; Hogstrom KR; Brown TA; Ii KL; Dugas JP; Ham K; Varnes ME
    Radiat Res; 2014 Dec; 182(6):607-17. PubMed ID: 25409122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretical basis and clinical methodology for stereotactic interstitial brain tumor irradiation using iododeoxyuridine as a radiation sensitizer and 145Sm as a brachytherapy source.
    Goodman JH; Gahbauer RA; Kanellitsas C; Clendenon NR; Laster BH; Fairchild RG
    Stereotact Funct Neurosurg; 1990; 54-55():531-4. PubMed ID: 1964244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced IUdR radiosensitization by 241Am photons relative to 226Ra and 125I photons at 0.72 Gy/hr.
    Nath R; Bongiorni P; Rossi PI; Rockwell S
    Int J Radiat Oncol Biol Phys; 1990 Jun; 18(6):1377-85. PubMed ID: 2370187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New compounds for neutron capture therapy (NCT) and their significance.
    Fairchild RG; Bond VP
    Strahlentherapie; 1984 Dec; 160(12):764-70. PubMed ID: 6393459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of IUdR radiosensitization by low energy photons.
    Nath R; Bongiorni P; Rockwell S
    Int J Radiat Oncol Biol Phys; 1987 Jul; 13(7):1071-9. PubMed ID: 3597150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
    Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
    Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological effects of particle radiation].
    Sakamoto K
    Gan No Rinsho; 1988 Oct; 34(13):1823-31. PubMed ID: 3143841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
    Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
    Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress in heavy particle radiotherapy].
    Tsujii H; Tsuji H; Okumura T
    Gan To Kagaku Ryoho; 1994 Jun; 21(7):929-35. PubMed ID: 8002630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.
    Taverna P; Hwang HS; Schupp JE; Radivoyevitch T; Session NN; Reddy G; Zarling DA; Kinsella TJ
    Cancer Res; 2003 Feb; 63(4):838-46. PubMed ID: 12591735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine).
    Otto SE
    J Intraven Nurs; 1998; 21(6):335-7. PubMed ID: 10392098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Objective for clinical use of particle radiations with high LET].
    Tsunemoto H
    Gan No Rinsho; 1985 Sep; 31(12):1563-5. PubMed ID: 3001382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermal sensitivity and radiosensitization in V79 cells after BrdUrd or IdUrd incorporation.
    Raaphorst GP; Vadasz JA; Azzam EI
    Radiat Res; 1984 Apr; 98(1):167-75. PubMed ID: 6718691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
    McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
    Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiobiology and clinical application of halogenated pyrimidine radiosensitizers.
    Mitchell JB; Russo A; Cook JA; Straus KL; Glatstein E
    Int J Radiat Biol; 1989 Nov; 56(5):827-36. PubMed ID: 2573682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.